Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia.

Antimicrobial Agents and Chemotherapy
Abla TannousMark J DiNubile

Abstract

There remains an unmet need to address the substantial morbidity and mortality associated with severe community-acquired pneumonia (sCAP). Recombinant human plasma gelsolin (rhu-pGSN) improves disease outcomes in diverse animal models of infectious and noninfectious inflammation. This blinded dose-escalation safety study involved non-intensive care unit (ICU) patients admitted for mild CAP and randomized 3:1 to receive adjunctive rhu-pGSN or placebo intravenously. Thirty-three subjects were treated: 8 in the single-dose phase and 25 in the multidose phase. For the single-dose phase, rhu-pGSN at 6 mg/kg of body weight was administered once. For the multidose phase, a daily rhu-pGSN dose of 6, 12, or 24 mg/kg was given on 3 consecutive days. Adverse events (AEs) were generally mild in both treatment groups irrespective of dose. The only serious AE (SAE) in the single-dose phase was a non-drug-related pneumonia in a rhu-pGSN recipient who died after institution of comfort care. One single-dose placebo recipient had a drug-related AE (maculo-papular rash). In the multidose phase, there were 2 SAEs in 1 placebo recipient, including a fatal pulmonary embolism. In the 18 rhu-pGSN recipients in the multidose phase, there were no seriou...Continue Reading

References

May 14, 1992·The New England Journal of Medicine·W M Lee, R M Galbraith
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J G HaddadJ W Sanger
Sep 1, 1986·The Journal of Clinical Investigation·S E LindT P Stossel
Dec 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·E Lazarides, U Lindberg
Feb 18, 1994·Science·C A VasconcellosT P Stossel
Nov 11, 1999·American Journal of Respiratory and Critical Care Medicine·K C MounzerM J Dinubile
May 9, 2000·The Journal of Biological Chemistry·E J GoetzlJ S Karliner
Jul 21, 2000·American Journal of Respiratory and Critical Care Medicine·J A ErukhimovB R Pitt
May 6, 2003·Journal of Applied Physiology·Patricia A RothenbachRichard H Turnage
Jul 13, 2005·Biochemistry·Robert BuckiPaul A Janmey
Feb 24, 2006·Annals of Surgery·Po-Shun LeeSelwyn O Rogers
Dec 1, 2006·American Journal of Physiology. Cell Physiology·Teresia M OsbornThomas P Stossel
Sep 20, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Robert BuckiPaul A Janmey
Sep 30, 2008·Arthritis Research & Therapy·Teresia M OsbornMaria Bokarewa
Nov 13, 2008·PloS One·Po-Shun LeeAaron B Waxman
Sep 3, 2010·American Journal of Physiology. Cell Physiology·Robert BuckiPaul A Janmey
Nov 13, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Dong-Qing ZhaoYu-Jian Li
Jun 12, 2013·Cytoskeleton·Shalini NagLeslie D Burtnick
Jul 25, 2013·Critical Care : the Official Journal of the Critical Care Forum·Jian-Wei PanRen-Ya Zhan
May 10, 2015·American Journal of Physiology. Lung Cellular and Molecular Physiology·Zhiping YangLester Kobzik
Jul 15, 2015·The New England Journal of Medicine·Seema JainUNKNOWN CDC EPIC Study Team
Oct 7, 2015·Journal of Neuroimmunology·Kevin Li-ChunHsiehJohn W Chen
Feb 24, 2016·JAMA : the Journal of the American Medical Association·Mervyn SingerDerek C Angus
Apr 8, 2017·American Journal of Physiology. Lung Cellular and Molecular Physiology·Christine M OrdijaLester Kobzik
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Julio A RamirezUNKNOWN University of Louisville Pneumonia Study Group
Dec 19, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Wesley H SelfCarlos G Grijalva
Apr 9, 2019·The Medical Clinics of North America·Charles W LanksDavid W Hsia

❮ Previous
Next ❯

Citations

Aug 17, 2021·Clinical Infection in Practice·Julie V Catteeuw, Mark J DiNubile

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.